

IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE

CEPHALON, INC.,	)	
	)	
Plaintiff,	)	
	)	
v.	)	C.A. No. _____
	)	
EAGLE PHARMACEUTICALS, INC.,	)	
	)	
Defendant.	)	

**COMPLAINT**

Cephalon, Inc. (“Cephalon” or “Plaintiff”) brings this action for patent infringement against Defendant Eagle Pharmaceuticals, Inc. (“Eagle” or “Defendant”).

1. This is an action by Cephalon against Defendant for infringement of United States Patent No. 8,791,270 (“the ’270 patent”). This action arises out of Defendant’s filing of a New Drug Application (“NDA”) seeking approval by the United States Food and Drug Administration (“FDA”) to sell liquid concentrate versions of TREANDA<sup>®</sup>, Cephalon’s innovative treatment for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, prior to the expiration of the ’270 patent.

**THE PARTIES**

**Cephalon, Inc.**

2. Plaintiff Cephalon, Inc. is a corporation operating and existing under the laws of Delaware, with its principal place of business at 41 Moores Road, Frazer, Pennsylvania 19355. Cephalon is engaged in the business of research, development, manufacture, and sale of innovative pharmaceutical products throughout the world.

**Eagle Pharmaceuticals, Inc.**

3. Upon information and belief, Defendant Eagle Pharmaceuticals, Inc. is a corporation operating and existing under the laws of Delaware, with its principal place of business at 470 Chestnut Ridge Road, Woodcliff Lake, New Jersey 07677. Eagle has designated Corporation Service Company at 2711 Centerville Rd., Suite 400, Wilmington, DE 19808 for receipt of service in the State of Delaware.

**JURISDICTION AND VENUE**

**Subject Matter Jurisdiction**

4. This action for patent infringement arises under 35 U.S.C. § 271.

5. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331 and 1338(a), and the Declaratory Judgment Act, 28 U.S.C §§ 2201 and 2202.

**Personal Jurisdiction Over Eagle**

6. Upon information and belief, this Court has personal jurisdiction over Eagle at least because Eagle: (1) is incorporated in Delaware and conducts business in this Judicial District; and (2) has engaged in continuous and systematic contacts with Delaware and/or purposefully availed itself of this forum by, among other things, making, shipping, using, offering to sell or selling, or causing others to use, offer to sell, or sell, Eagle pharmaceutical products in this Judicial District, and deriving substantial revenue from such activities.

7. Upon information and belief, this Court also has personal jurisdiction over Defendant because it previously has been sued in this district, did not challenge this Court's assertion of personal jurisdiction over it, and availed itself of this forum by asserting counterclaims for the purpose of litigating a patent infringement dispute. *See Cephalon, Inc. v. Eagle Pharmaceuticals, Inc.*, C.A. No. 13-1738 (D. Del).

## Venue

8. Venue is proper in this Judicial District under 28 U.S.C. §§ 1391 and 1400(b).

## **BACKGROUND**

### The Patent-in-Suit

9. The '270 patent, entitled "Bendamustine Pharmaceutical Compositions," was duly and lawfully issued on July 29, 2014 to inventors Jason E. Brittain and Joe C. Franklin.

10. The named inventors of the '270 patent assigned their rights in the '270 patent to Cephalon.

11. Cephalon is the sole owner by assignment of all rights, title and interest in the '270 patent.

12. The '270 patent is listed in FDA publication "Approved Drug Products with Therapeutic Equivalence Evaluations," commonly referred to as "The Orange Book" ("Orange Book"), with respect to TREANDA<sup>®</sup>.

13. The '270 patent will expire on January 12, 2026. A true and accurate copy of the '270 patent is attached hereto as Exhibit A.

### The TREANDA<sup>®</sup> Drug Product

14. Cephalon researched, developed, applied for and obtained FDA approval to manufacture, sell, promote and/or market bendamustine hydrochloride products known as TREANDA<sup>®</sup>.

15. Cephalon has been selling, promoting, distributing and marketing TREANDA<sup>®</sup> in the United States since 2008.

16. TREANDA<sup>®</sup> is indicated to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

17. Cephalon holds New Drug Application No. 22249 and No. 22303 under Section 505(a) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(a), for multiple TREANDA<sup>®</sup> products used for treating chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

**The Eagle NDA and Eagle's Bendamustine Product**

18. Eagle filed with FDA in Rockville, Maryland, a New Drug Application under 21 U.S.C. § 355(b)(2) seeking approval to manufacture, use, offer for sale, sell in and import into the United States a 100 mg/4 mL (25 mg/mL) liquid concentrate bendamustine hydrochloride product ("Eagle's Bendamustine Product") prior to the expiration of the '270 patent.

19. FDA assigned the NDA for Eagle's Bendamustine Product the number 205580.

20. Upon information and belief, Eagle has received tentative approval from FDA for Eagle's Bendamustine Product.

21. Upon information and belief, the U.S. Patent Office has issued patent 8,609,707 for Eagle's Bendamustine Product. (See <http://eaglepharm.investorhq.businesswire.com/press-release/eagle-pharmaceuticals-receives-tentative-approval-patented-ready-dilute-bendamustine-h>.)

22. Upon information and belief, the U.S. Patent and Trademark Office has published U.S. Patent Application Publication No. 2013/0210879, which discloses Eagle's Bendamustine Product.

**The Ongoing Litigation**

23. In connection with its NDA, Eagle also filed with FDA, pursuant to 21 U.S.C. § 355(b)(2)(A)(iv), a certification alleging that the claims of another Cephalon patent, U.S. Patent No. 8,445,524 ("the '524 patent") are invalid, unenforceable and/or would not be

infringed by the manufacture, use, importation, sale or offer for sale of Eagle's Bendamustine Product ("Eagle's Paragraph IV Certification").

24. By letter dated September 6, 2013, Eagle notified Cephalon that it had filed NDA 205580 seeking approval to market Eagle's Bendamustine Product prior to the expiration of the '524 patent ("Eagle Notice Letter").

25. Pursuant to an Offer of Confidential Access, Cephalon reviewed portions of the NDA filed by Eagle for information related to the '524 patent.

26. On October 21, 2013, Cephalon sued Eagle for patent infringement of the '524 patent in the District of Delaware. *See Cephalon, Inc. v. Eagle Pharmaceuticals, Inc.*, C.A. No. 13-1738 (D. Del). That action was commenced before the expiration of forty-five days from the date of receipt of the Eagle Notice Letter.

**COUNT I DECLARATORY JUDGMENT OF  
INFRINGEMENT OF U.S. PATENT NO. 8,791,270 BY EAGLE**

27. The allegations of the proceeding paragraphs 1–26 are re-alleged and incorporated herein by reference.

28. Cephalon notified Eagle of the issuance of the '270 patent before filing this action.

29. Upon information and belief, Eagle's Bendamustine Product contains the same active pharmaceutical ingredient, bendamustine hydrochloride, as that used in Cephalon's TREANDA<sup>®</sup> products and claimed in the '270 patent.

30. Upon information and belief, Eagle's Bendamustine Product is the pharmaceutical composition of bendamustine hydrochloride, containing less than or equal to 4.0% (area percent of bendamustine) of bendamustine degradants, recited in one or more claims of the '270 patent.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.